{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:35:44Z","timestamp":1794242144389,"version":"4.9.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.critrevonc.2021.103294","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T23:16:36Z","timestamp":1614986196000},"page":"103294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment \u2013 A systematic review"],"prefix":"10.1016","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3390-3295","authenticated-orcid":false,"given":"Alda","family":"Tavares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-451X","authenticated-orcid":false,"given":"Il\u00eddia","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2021.103294_bib0005","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3109\/10428194.2013.780654","article-title":"Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma","volume":"54","author":"Aoki","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103294_bib0010","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00277-017-3017-7","article-title":"Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma","volume":"96","author":"Arakaki","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2021.103294_bib0015","first-page":"1","article-title":"A real-world study of first-line therapy in 280 consecutive Swedish patients \u226580 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (\u226585 years) do well on curative intended therapy","author":"Asklid","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2021.103294_bib0020","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0738","article-title":"Comprehensive geriatric assessment (CGA): a simple tool for guiding the treatment of older adults with diffuse large B-Cell lymphoma in China","author":"Bai","year":"2020","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103294_bib0025","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1080\/10428194.2018.1443332","article-title":"Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era","volume":"59","author":"Beygi","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103294_bib0030","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ejh.13069","article-title":"Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma","volume":"101","author":"Cheng","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"2 Suppl 6","key":"10.1016\/j.critrevonc.2021.103294_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/sonc.2002.32749","article-title":"Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"29","author":"Coiffier","year":"2002","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103294_bib0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2011.08786.x","article-title":"Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high\u2019 life threat\u2019 impact cardiopathy","volume":"154","author":"Corazzelli","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"9880","key":"10.1016\/j.critrevonc.2021.103294_bib0050","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103294_bib0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103294_bib0060","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3109\/10428194.2011.572321","article-title":"Non-pegylated liposomal doxorubicin (Myocet\u00ae) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma","volume":"52","author":"Dell\u2019Olio","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"18","key":"10.1016\/j.critrevonc.2021.103294_bib0065","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103294_bib0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103294_bib0075","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.2019-0286","article-title":"Phase II study of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-Cell lymphoma who are poor candidates for R-CHOP chemotherapy","volume":"24","author":"Flinn","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103294_bib0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.leukres.2010.07.024","article-title":"Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma","volume":"35","author":"Gimeno","year":"2011","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","article-title":"Brief-duration rituximab\/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah cannon oncology research consortium","volume":"10","author":"Hainsworth","year":"2010","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2021.103294_bib0090","unstructured":"N. Howlader , A. Noone , M. Krapcho , D. Miller , A. Brest , M. Yu , J. Ruhl , Z. Tatalovich , A. Mariotto , D. Lewis , H. Chen , E. Feuer , K. Cronin . SEER Cancer Statistics Review, 1975-2017, National Cancer Institute https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html https:\/\/seer.cancer.gov\/csr\/1975_2017\/results_merged\/sect_19_nhl.pdf."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103294_bib0095","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10147-015-0912-6","article-title":"Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy","volume":"21","author":"Iioka","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103294_bib0100","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.12459","article-title":"Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: consortium for improving survival of lymphoma study (CISL)","volume":"94","author":"Jung","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103294_bib0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3109\/10428194.2011.555024","article-title":"Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma","volume":"52","author":"Kasahara","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/10245332.2018.1509461","article-title":"Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma","volume":"24","author":"Kayamori","year":"2019","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103294_bib0115","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2011-10-388470","article-title":"Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma","volume":"119","author":"Klapper","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/ejh.12304","article-title":"R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma","volume":"93","author":"Kreher","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103294_bib0125","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","article-title":"R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma","volume":"95","author":"Laribi","year":"2016","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103294_bib0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2012.09177.x","article-title":"Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis","volume":"158","author":"Lee","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103294_bib0135","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdp544","article-title":"Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.600486","article-title":"Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older","volume":"53","author":"Meguro","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103294_bib0145","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/10428194.2011.621565","volume":"53","author":"Merli","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jgo.2019.06.020","article-title":"Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi","volume":"11","author":"Merli","year":"2020","journal-title":"J. Geriatr. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103294_bib0155","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103294_bib0160","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/annonc\/mdv018","article-title":"Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary","volume":"26","author":"Morrison","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103294_bib0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","article-title":"Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper","volume":"6","author":"Morrison","year":"2015","journal-title":"J. Geriatr. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103294_bib0170","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/cncr.25582","article-title":"Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma","volume":"117","author":"Musolino","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103294_bib0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","article-title":"Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial","volume":"15","author":"Oki","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103294_bib0180","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1634\/theoncologist.2011-0355","article-title":"Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA","volume":"17","author":"Olivieri","year":"2012","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103294_bib0185","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ajh.25107","article-title":"A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: a multicenter, retrospective analysis by the Spanish GELTAMO group","volume":"93","author":"Pardal","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103294_bib0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103294_bib0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clml.2018.11.003","article-title":"Multicenter phase 2 study of reduced-dose CHOP chemotherapy combined with rituximab for elderly patients with diffuse large B-Cell lymphoma","volume":"19","author":"Park","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103294_bib0200","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Investigators, G. D. E. D. L. D. L. A. G., attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0205","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103294_bib0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"(DSHNHL), G. H.-G. N.-H. L. S. G., Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103294_bib0215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hon.2386","article-title":"Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study","volume":"36","author":"Ricciuti","year":"2018","journal-title":"Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103294_bib0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00130404-200511000-00004","article-title":"Physiologic aspects of aging: impact on cancer management and decision making, part I","volume":"11","author":"Sawhney","year":"2005","journal-title":"Cancer J."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103294_bib0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00130404-200511000-00005","article-title":"Physiologic aspects of aging: impact on cancer management and decision making, part II","volume":"11","author":"Sehl","year":"2005","journal-title":"Cancer J."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103294_bib0230","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","article-title":"Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103294_bib0235","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-011-1814-6","article-title":"Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma","volume":"69","author":"Shin","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103294_bib0240","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","article-title":"Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma","volume":"17","author":"Spina","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103294_bib0245","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (&70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.critrevonc.2021.103294_bib0250","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.2169\/internalmedicine.0990-18","article-title":"The prognostic impact of dose-attenuated R-CHOP therapy for elderly patients with diffuse large B-cell lymphoma","volume":"57","author":"Tanimura","year":"2018","journal-title":"Intern. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103294_bib0255","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hon.815","article-title":"A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma","volume":"25","author":"Tsurumi","year":"2007","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103294_bib0260","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"(FIL), I. L. F., Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103294_bib0265","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","article-title":"Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas","volume":"22","author":"Weidmann","year":"2011","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103294_bib0270","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00277-019-03819-3","article-title":"Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study","volume":"98","author":"Zeremski","year":"2019","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103294_bib0275","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00277-018-3369-7","article-title":"Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma","volume":"97","author":"Zhang","year":"2018","journal-title":"Ann. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:38:13Z","timestamp":1760902693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":55,"alternative-id":["S1040842821000822"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103294","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103294"}}